Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease"
Am J Respir Crit Care Med
.
2017 Oct 15;196(8):1083-1084.
doi: 10.1164/rccm.201704-0818LE.
Authors
David A Lipson
1
2
,
Helen Barnacle
3
,
Ruby Birk
3
,
Noushin Brealey
3
,
Nicholas Locantore
1
,
David A Lomas
4
,
Andrea Ludwig-Sengpiel
5
,
Rajat Mohindra
3
,
Maggie Tabberer
3
,
Chang-Qing Zhu
3
,
Steven J Pascoe
1
Affiliations
1
1 GlaxoSmithKline King of Prussia, Pennsylvania.
2
2 University of Pennsylvania Philadelphia, Pennsylvania.
3
3 GlaxoSmithKline Uxbridge, United Kingdom.
4
4 University College London London, United Kingdom and.
5
5 KLB Health Research Lübeck, Germany.
PMID:
28534669
DOI:
10.1164/rccm.201704-0818LE
No abstract available
Publication types
Comment
MeSH terms
Bronchodilator Agents*
Humans
Pulmonary Disease, Chronic Obstructive*
Substances
Bronchodilator Agents
Grants and funding
MR/N024842/1/MRC_/Medical Research Council/United Kingdom